Pharmaceutical Raw Materials
Veterinary API
Antiallergic Drugs
Hormones and Endocrine Drugs
Drug Metabolism
Pharmaceutical Intermediates
Synthetic Anti Infective Drugs
Specialty Drugs
Vitamins and Minerals Medicines
Feed Drug Additive
Antineoplastic Agents
Nervous System Drugs
Respiratory Drugs
Diagnostic Agents
Anti Stress Drugs
Antipyretic Analgesics
Antiparasitic Drugs
Circulatory System Drugs
Biochemicals
Blood System Drugs
Immune System Medication
Pharmaceutical Excipients
Fluid, Electrolyte, and Acid-Base Balance
Urinary System Drugs
Antibiotics
Anesthetic Agents
Inhibitors
Other Chemical Drugs
Digestive System Drugs
CAS:223673-61-8
Molecular Formula:C21H24N4O2S
Alias
More Information
N-(4-(2-(2-Hydroxy-2-Phenylethylamino)Ethyl)Phenyl)-2-(2-Aminothiazol-4-Yl)Acetamide; Ym-178; Mirabeqron; 2-Amino-N-[4-[2-[[(2R)-2-Hydroxy-2-Phenyl-Ethyl]Amino]-Ethyl]Phenyl]-4-Thiazoleacetamide; 2-(2-Amino-1,3-Thiazol-4-Yl)-N-(4-{2-[(2-Hydroxy-2-Phenylethyl)Amino]Ethyl}Phenyl)Acetamide; 4-Thiazoleacetamide, 2-Amino-N-(4-(2-(((2R)-2-Hydroxy-2-Phenylethyl)Amino)Ethyl)Phenyl)-
Brief Introduction
Mirabelon tablets, developed by Estelle pharmaceutical company of Japan, were listed in Japan on September 16, 2011 and approved by the US Food and Drug Administration (FDA) on June 28, 2012 for the treatment of adult overactive bladder (OAB). Mirabelon was the first to be used to treat overactive bladder β 3. Adrenoceptor agonists, whose successful marketing fills the gap β There is a blank of adrenoceptor agonists in the treatment of overactive bladder.
Suppliers
View More Vendors (4） >
CAS:461432-26-8
Molecular Formula:C21H25ClO6
Alias
More Information
[14C]-Dapagliflozin; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[(4-Ethoxyphenyl)Methyl]Phenyl]-6-(Hydroxymethyl)Oxane-3,4,5-Triol; D-Glucitol,1,5-Anhydro-1-C-[4-Chloro-3-[(4-Ethoxyphenyl)Methyl]Phenyl]-,(1S); Dapaglifozin; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-Ethoxybenzyl)Phenyl]-6-(Hydroxymethy)Tetrahydro-2H-Pyran-3,4,5-Triol; Forxiga (Tn); (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-Ethoxybenzyl)Phenyl]-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-3,4,5-Triol
Brief Introduction
Dagglitazin is a sodium glucose cotransporter 2 inhibitor (sglt2i), which is a new oral hypoglycemic drug. It can inhibit SGLT2 activity, inhibit sodium glucose reabsorption in proximal renal tubules, promote urinary glucose excretion, and reduce blood glucose concentration.
Suppliers
View More Vendors (3） >
CAS:737789-87-6
Molecular Formula:C29H29F2N7O5S
Alias
More Information
1-(4-(1-(2,6-Difluorobenzyl)-5-((Dimethylamino)Methyl)-3-(6-Methoxypyridazin-3-yl)-2,4-Dioxo-1,2,3,4-Tetrahydrothieno[2,3-d]Pyrimidin-6-yl)Phenyl)-3-Methoxyurea; TAK-385
Brief Introduction
Relugolix is an oral gonadotropin releasing hormone receptor antagonist
Suppliers
View More Vendors (3） >
CAS:70024-40-7
Molecular Formula:C19H30ClN5O6
Alias
More Information
[4-(4-Amino-6,7-Dimethoxyquinazolin-2-yl)Piperazin-1-yl]-(Oxolan-2-yl)Methanone,Dihydrate,Hydrochloride; Magnurol; Terazosin Hydrochloride Dihydrate; Terazosin HCl Dihydrate
Brief Introduction
Terazosin HCl is α- Adrenergic receptor inhibitors for the treatment of hypertension and prostate hypertrophy.
Suppliers
View More Vendors (2） >
CAS:149709-62-6
Molecular Formula:C24H29NO5
Alias
More Information
Entresto (Trade Name, With Valsartan Sodium); 4-[[(2S,4R)-5-Ethoxy-4-Methyl-5-Oxo-1-(4-Phenylphenyl)Pentan-2-Yl]Amino]-4-Oxobutanoic Acid; Ahu-377; 4-(((2S,4R)-1-([1,1'-Biphenyl]-4-Yl)-5-Ethoxy-4-Methyl-5-Oxopentan-2-Yl)Amino)-4-Oxobutanoic Acid; 4-(((2R,4R)-1-([1,1'-Biphenyl]-4-Yl)-5-Ethoxy-4-Methyl-5-Oxopentan-2-Yl)Amino)-4-Oxobutanoic Acid; (2R,4S)-5-(Biphenyl-4-Yl)-4-[(3-Carboxypropionyl)Amino]-2-Methylpentanoic Acid Ethyl Ester; (2R,4S)-5-([1,1'-Biphenyl]-4-Yl)-4-(3-Carboxypropanamido)-2-Methylpentanoic Acid; Ahu-377,149709-62-6; Ahu-37; Ahu377; Ahu 377
Brief Introduction
Sacubitril (INN developmental code name AHU-377) is an antihypertensive drug used in combination with valsartan. The combination drug valsartan/sacubitril, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. It was approved under the FDA's priority review process for use in heart failure on July 7, 2015.
Suppliers
View More Vendors (2） >
Shandong Joyochem,Co.,Ltd.
≥99%
/
-
Inquiry (
10
/ 10
)
Clear All
Sign In
Error!